Literature DB >> 21541103

Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.

Rebecca Ronsley1, Kamini Raghuram, Jana Davidson, Constadina Panagiotopoulos.   

Abstract

OBJECTIVE: 1) Assess perceived barriers associated with metabolic monitoring in second-generation antipsychotic (SGA)-treated youth; and 2) Propose a metabolic monitoring protocol (MMP) and implementation strategies.
METHOD: Online surveys were created for community mental health teams (CMHTs) and BC Children's Hospital (BCCH) with questions designed to evaluate knowledge of physical health care, confidence, communication with primary care, and practical issues.
RESULTS: 26/50 (52%) of CMHT and 44/111 (40%) of BCCH surveys were completed. While both groups agreed that monitoring is their responsibility, 26% of CMHTs and 35% of BCCH professionals agreed that providing information about SGA side-effects would influence medication adherence. CMHTs reported lower overall confidence and more practical issues as monitoring barriers. While higher overall confidence was reported at BCCH, there was still a substantial proportion (23%) of hospital professionals who reported not knowing what parameters to monitor and how frequently. Communication with primary care, including inadequate systems for sharing results and identifying responsibility for acting on abnormal results, appear to be common barriers shared by both settings.
CONCLUSIONS: Barriers to metabolic monitoring were more frequently reported by CMHTs who had limited access to nursing staff. We propose hands-on training, educational resources, pre-printed orders, and regular quality assurance evaluation as facilitators to promote MMP uptake.

Entities:  

Keywords:  adolescents; atypical antipsychotics; children; efficacy; metabolic monitoring

Year:  2011        PMID: 21541103      PMCID: PMC3085673     

Source DB:  PubMed          Journal:  J Can Acad Child Adolesc Psychiatry        ISSN: 1719-8429


  20 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B.

Authors:  Laura C Scarlota; John A Harvey; Vincent J Aloyo
Journal:  Psychopharmacology (Berl)       Date:  2010-07-21       Impact factor: 4.530

Review 3.  Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.

Authors:  Arshia A Shirzadi; S Nassir Ghaemi
Journal:  Harv Rev Psychiatry       Date:  2006 May-Jun       Impact factor: 3.732

4.  Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

Authors:  Ren-Rong Wu; Jing-Ping Zhao; Zhe-Ning Liu; Jin-Guo Zhai; Xiao-Feng Guo; Wen-Bing Guo; Jing-Song Tang
Journal:  Psychopharmacology (Berl)       Date:  2006-04-07       Impact factor: 4.530

5.  The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.

Authors:  John W Newcomer; Henry A Nasrallah; Antony D Loebel
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

6.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

7.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Authors:  Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

Review 8.  Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.

Authors:  D Cohen
Journal:  Pharmacopsychiatry       Date:  2004-01       Impact factor: 5.788

9.  Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.

Authors:  Garry Walter; Amy DeLaroche; Nerissa Soh; Glenn Hunt; Michelle Cleary; Gin Malhi; Tim Lambert; Christoph Correll; Joseph Rey
Journal:  Australas Psychiatry       Date:  2008-08       Impact factor: 1.369

Review 10.  The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects.

Authors:  R Tandon; U Halbreich
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905

View more
  7 in total

1. 

Authors:  Clare Lambert; Constadina Panagiotopoulos; Jana Davidson; Ran D Goldman
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

2.  Second-generation antipsychotics in children: Risks and monitoring needs.

Authors:  Clare Lambert; Constadina Panagiotopoulos; Jana Davidson; Ran D Goldman
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

3.  Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy.

Authors:  Yasuyuki Okumura; Masahide Usami; Takashi Okada; Takuya Saito; Hideki Negoro; Noa Tsujii; Junichi Fujita; Junzo Iida
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-06-11       Impact factor: 2.576

4.  Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review.

Authors:  Gian Loreto D'Alò; Franco De Crescenzo; Laura Amato; Fabio Cruciani; Marina Davoli; Francesca Fulceri; Silvia Minozzi; Zuzana Mitrova; Gian Paolo Morgano; Franco Nardocci; Rosella Saulle; Holger Jens Schünemann; Maria Luisa Scattoni
Journal:  BMC Psychiatry       Date:  2020-11-25       Impact factor: 3.630

5.  Monitoring of Adverse Drug Reaction-Related Parameters in Children and Adolescents Treated With Antipsychotic Drugs in Psychiatric Outpatient Clinics.

Authors:  Lenneke Minjon; Ivona Brozina; Toine C G Egberts; Eibert R Heerdink; Els van den Ban
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

6.  Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners.

Authors:  Lenneke Minjon; Els van den Ban; Marloes T Bazelier; Arief Lalmohamed; Toine C G Egberts; Eibert R Heerdink
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-10-07       Impact factor: 2.576

7.  Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Métabolique à Long Terme des Jeunes Traités par Antipsychotiques de Deuxième Génération, Cinq ans Après la publication des Lignes Directrices Camesa: Faisons-Nous des Progrès?

Authors:  Sarra Jazi; Leila Ben-Amor; Pascale Abadie; Marie-Line Menard; Rachel Choquette; Claude Berthiaume; Laurent Mottron; Drigissa Ilies
Journal:  Can J Psychiatry       Date:  2020-11-26       Impact factor: 4.356

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.